TWM
NVS icon

Titus Wealth Management’s Novartis NVS Stock Holding History

Titus Wealth Management’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,445
Closed -$201K – 88
2017
Q4 		$201K Buy
+2,445
New +$184K 0.23% 75

Other funds holding NVS

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return
BBHC
Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Titus Wealth Management's NVS Position: Q1 2018 in Review

Titus Wealth Management sold out of Novartis (NVS) in Q1 2018, closing a stake of 2,445 shares — an estimated $201K sold.

Titus Wealth Management first reported a position in NVS in Q4 2017 and held it in 1 quarter. The position peaked at $201K in Q4 2017. 1,012 funds tracked by Wall St. Rank hold NVS as of Q1 2018.

  • Titus Wealth Management reported no remaining Novartis position as of Q1 2018 after selling out during the quarter.
  • Titus Wealth Management sold 2,445 Novartis shares in Q1 2018, an estimated $201K.
  • Titus Wealth Management first reported a position in Novartis in Q4 2017 and held it in 1 quarter.
  • Titus Wealth Management's Novartis position peaked at $201K in Q4 2017.
  • 1,012 funds tracked by Wall St. Rank held Novartis as of Q1 2018.

Based on Titus Wealth Management's 13F filing for Q1 2018, filed 15 May 2018.